TELA Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
19.0M
-1.7%
19.3M
+1.2%
19.1M
-8.7%
20.9M
+0.9%
20.7M
Cost of Revenue
8.6M
+61.5%
5.3M
-18.2%
6.5M
-8.1%
7.1M
+3.4%
6.9M
Gross Profit
10.3M
-26.0%
13.9M
+11.4%
12.5M
-9.0%
13.8M
-0.4%
13.8M
Operating Expenses
17.6M
-24.2%
23.2M
+0.8%
23.0M
+13.0%
20.4M
-4.5%
21.4M
R&D
1.6M
-41.1%
2.7M
+16.2%
2.3M
+10.1%
2.1M
-9.3%
2.3M
SG&A
16.0M
-21.9%
20.5M
-1.0%
20.7M
+13.3%
18.3M
-3.9%
19.0M
Operating Income
-7290000
+21.5%
-9283000
+11.8%
-10526000
-58.3%
-6648000
+12.0%
-7554000
EBITDA
-7023000
+22.1%
-9017000
+12.1%
-10262000
-59.8%
-6423000
+12.1%
-7306000
Net Income
-9302000
+17.4%
-11262000
+8.2%
-12273000
-35.7%
-9041000
-5.1%
-8603000
EPS (Basic)
$-0.16
+20.0%
$-0.20
+4.8%
$-0.21
-23.5%
$-0.17
+10.5%
$-0.19
EPS (Diluted)
$-0.16
+20.0%
$-0.20
+4.8%
$-0.21
-23.5%
$-0.17
+10.5%
$-0.19
Shares (Diluted)
57.7M
+0.5%
57.4M
+0.3%
57.3M
+10.7%
51.7M
+13.9%
45.4M
TELA Bio (TELA) — Financials